Drugs.com Clinical Trial ResultsOriginal article
UTR Therapeutics Inc. Announces U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14
RegulatoryUTRxMYCN M1-14Positive
AI Analysis
Summary
UTR Therapeutics announced that its RNA therapeutic UTRxMYCN M1-14 received U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation. These regulatory designations provide development support and potential commercial benefits for rare pediatric conditions.
Outcome Details
U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation granted
Importance:5/10
Sentiment:
0.70
orphan_drug_designationrare_pediatric_disease_designationRNA_therapeuticsregulatory
Read the original article
Published by Drugs.com Clinical Trial Results on October 1, 2026 1:10 AM